Bolt Biotherapeutics Schedules Annual Meeting, Discloses High Executive Compensation and Governance Lapses Amidst Going Concern
BOLT sits 24% above its 52-week low of $3.91 on light trading volume (0.3× avg).
Summary
Bolt Biotherapeutics filed its definitive proxy statement for its annual meeting, revealing high executive compensation, a 2025 stock option repricing, and several governance issues, all against the backdrop of a going concern warning.
Key Events · Corporate Governance and Compliance · BOLT
-
Annual Shareholder Meeting Scheduled
The company will hold its annual meeting on June 10, 2026, to elect two Class II directors and ratify PricewaterhouseCoopers LLP as its independent registered public accounting firm for 2026.
-
Significant Executive Compensation Disclosed
In 2025, CEO William P. Quinn received total compensation of $4.56 million, including $3.67 million in option awards, and COO Grant Yonehiro received $4.01 million, including $3.24 million in option awards. These figures represent a substantial portion of the company's market capitalization, particularly in the context of a going concern warning.
-
Stock Option Repricing in 2025
In December 2025, the Board approved repricing outstanding stock options with exercise prices greater than $5.44 to an exercise price of $5.44 per share. While the current stock price is $4.84, this repricing was a significant re-incentivization effort following a stock price decline.
-
Director Independence and Compliance Issues
Director Jakob Dupont, M.D. is no longer considered independent due to receiving over $120,000 in consulting compensation in 2025. Additionally, five directors (Laura Berner, Jakob Dupont, M.D., Kathleen LaPorte, Brian O'Callaghan, and Nicole Onetto, M.D.) had delinquent Section 16(a) filings for one transaction each.
Analysis · BOLT · Life Sciences
This definitive proxy statement reveals significant governance and compensation details for Bolt Biotherapeutics, a company operating under a going concern warning. The disclosure of substantial executive compensation, particularly the repricing of stock options in late 2025, raises concerns about capital allocation and shareholder value given the company's precarious financial position. Additionally, the loss of a director's independent status due to consulting fees and multiple Section 16(a) filing delinquencies indicate weaknesses in corporate governance. Investors should scrutinize these details in light of the company's ongoing financial challenges.
At the time of this filing, BOLT was trading at $4.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.3M. The 52-week trading range was $3.91 to $9.25. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.